Recro Pharma (NASDAQ:REPH) had its price target increased by research analysts at Stephens from $17.00 to $23.00 in a research report issued on Tuesday, The Fly reports. Stephens’ price target points to a potential upside of 34.50% from the company’s current price.
A number of other research firms have also recently commented on REPH. Oppenheimer set a $20.00 price target on Recro Pharma and gave the company a “buy” rating in a research note on Friday, August 9th. ValuEngine cut Recro Pharma from a “buy” rating to a “hold” rating in a research note on Tuesday, October 1st. BidaskClub upgraded Recro Pharma from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, October 22nd. Finally, Zacks Investment Research upgraded Recro Pharma from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Wednesday, October 30th. One research analyst has rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Recro Pharma has an average rating of “Buy” and a consensus target price of $15.70.
NASDAQ:REPH traded up $0.59 during midday trading on Tuesday, hitting $17.10. 427,700 shares of the company traded hands, compared to its average volume of 345,203. The firm has a market capitalization of $389.37 million, a P/E ratio of -6.87 and a beta of -0.40. Recro Pharma has a 12-month low of $5.53 and a 12-month high of $18.20. The firm’s fifty day moving average is $13.27 and its 200-day moving average is $10.98.
Recro Pharma (NASDAQ:REPH) last issued its quarterly earnings data on Friday, November 8th. The specialty pharmaceutical company reported ($0.19) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.13) by ($0.06). The company had revenue of $25.26 million during the quarter, compared to analysts’ expectations of $19.83 million. On average, analysts anticipate that Recro Pharma will post -0.54 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in REPH. Nuveen Asset Management LLC purchased a new stake in Recro Pharma in the second quarter valued at about $3,455,000. River & Mercantile Asset Management LLP purchased a new stake in Recro Pharma in the second quarter valued at about $2,166,000. BlackRock Inc. raised its stake in Recro Pharma by 14.9% in the second quarter. BlackRock Inc. now owns 1,292,173 shares of the specialty pharmaceutical company’s stock valued at $13,142,000 after buying an additional 167,346 shares during the last quarter. Wedge Capital Management L L P NC purchased a new stake in Recro Pharma in the second quarter valued at about $1,682,000. Finally, Penn Capital Management Co. Inc. purchased a new position in shares of Recro Pharma in the second quarter worth about $1,525,000. Institutional investors own 58.45% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc, a specialty pharmaceutical company, develops and commercializes products for hospital and related acute care settings. The company operates in two segments, Acute Care, and Contract Development and Manufacturing. Its lead product candidate includes injectable meloxicam, which completed pivotal phase III clinical trials for the treatment of post-operative pain.
Further Reading: Understanding Options Trading
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.